MarketPulse
L

$LGVN

3 articles found
2 positive
0 negative
1 neutral
BenzingaBenzinga··Usa News Group

Biotech Race to Commercialize Longevity Science Heats Up as Market Eyes $29.7B Prize

Longevity biotech sector surges toward $29.7B market by 2034 as companies advance cell therapies for age-related diseases, with multiple clinical programs showing promising results.
VRTXLGVNLCTXOCGNclinical trialsgene therapy
BenzingaBenzinga··Equity-Insider.Com

Biotech Breakthrough: Avaí Bio Moves Anti-Aging Protein Therapy Into Production

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.
MESOMNKDLGVNAVAILCTXregenerative medicinecell therapy
BenzingaBenzinga··Prnewswire

Cell Therapies Graduate to Mass Production as Market Eyes $8.2B Prize

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.
MESOFATEFBLGLGVNbiotechclinical trials